383 related articles for article (PubMed ID: 16113101)
1. Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation.
Martin LA; Farmer I; Johnston SR; Ali S; Dowsett M
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S75-84. PubMed ID: 16113101
[TBL] [Abstract][Full Text] [Related]
2. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation.
Martin LA; Farmer I; Johnston SR; Ali S; Marshall C; Dowsett M
J Biol Chem; 2003 Aug; 278(33):30458-68. PubMed ID: 12775708
[TBL] [Abstract][Full Text] [Related]
3. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation.
Chan CM; Martin LA; Johnston SR; Ali S; Dowsett M
J Steroid Biochem Mol Biol; 2002 Aug; 81(4-5):333-41. PubMed ID: 12361723
[TBL] [Abstract][Full Text] [Related]
4. The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling.
Martin LA; Pancholi S; Chan CM; Farmer I; Kimberley C; Dowsett M; Johnston SR
Endocr Relat Cancer; 2005 Dec; 12(4):1017-36. PubMed ID: 16322340
[TBL] [Abstract][Full Text] [Related]
5. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
[TBL] [Abstract][Full Text] [Related]
6. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
[TBL] [Abstract][Full Text] [Related]
7. Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model.
Staka CM; Nicholson RI; Gee JM
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S85-97. PubMed ID: 16113102
[TBL] [Abstract][Full Text] [Related]
8. Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity.
Santen RJ; Song RX; Zhang Z; Kumar R; Jeng MH; Masamura A; Lawrence J; Berstein L; Yue W
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S61-73. PubMed ID: 16113100
[TBL] [Abstract][Full Text] [Related]
9. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation.
Sabnis GJ; Jelovac D; Long B; Brodie A
Cancer Res; 2005 May; 65(9):3903-10. PubMed ID: 15867390
[TBL] [Abstract][Full Text] [Related]
10. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells.
Oh AS; Lorant LA; Holloway JN; Miller DL; Kern FG; El-Ashry D
Mol Endocrinol; 2001 Aug; 15(8):1344-59. PubMed ID: 11463858
[TBL] [Abstract][Full Text] [Related]
11. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
[TBL] [Abstract][Full Text] [Related]
12. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells.
Pietras RJ; Márquez DC; Chen HW; Tsai E; Weinberg O; Fishbein M
Steroids; 2005; 70(5-7):372-81. PubMed ID: 15862820
[TBL] [Abstract][Full Text] [Related]
13. Reactive oxygen species induce phosphorylation of serine 118 and 167 on estrogen receptor alpha.
Weitsman GE; Weebadda W; Ung K; Murphy LC
Breast Cancer Res Treat; 2009 Nov; 118(2):269-79. PubMed ID: 18941890
[TBL] [Abstract][Full Text] [Related]
14. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.
Britton DJ; Hutcheson IR; Knowlden JM; Barrow D; Giles M; McClelland RA; Gee JM; Nicholson RI
Breast Cancer Res Treat; 2006 Mar; 96(2):131-46. PubMed ID: 16261397
[TBL] [Abstract][Full Text] [Related]
15. Pentagalloylglucose inhibits estrogen receptor alpha by lysosome-dependent depletion and modulates ErbB/PI3K/Akt pathway in human breast cancer MCF-7 cells.
Hua KT; Way TD; Lin JK
Mol Carcinog; 2006 Aug; 45(8):551-60. PubMed ID: 16637063
[TBL] [Abstract][Full Text] [Related]
16. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells.
Yang Z; Barnes CJ; Kumar R
Clin Cancer Res; 2004 Jun; 10(11):3621-8. PubMed ID: 15173068
[TBL] [Abstract][Full Text] [Related]
17. Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells.
Murphy LC; Peng B; Lewis A; Davie JR; Leygue E; Kemp A; Ung K; Vendetti M; Shiu R
J Mol Endocrinol; 2005 Apr; 34(2):553-66. PubMed ID: 15821116
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells.
Jeng MH; Shupnik MA; Bender TP; Westin EH; Bandyopadhyay D; Kumar R; Masamura S; Santen RJ
Endocrinology; 1998 Oct; 139(10):4164-74. PubMed ID: 9751496
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Kurokawa H; Arteaga CL
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
[TBL] [Abstract][Full Text] [Related]
20. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.
Hutcheson IR; Knowlden JM; Madden TA; Barrow D; Gee JM; Wakeling AE; Nicholson RI
Breast Cancer Res Treat; 2003 Sep; 81(1):81-93. PubMed ID: 14531500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
